Year: 2024
Type: review
Abstract: PURPOSE OF REVIEW: The intestinal microbiome and the gut-liver axis play a major role in health and disease. The human gut harbors trillions of microbes and a disruption of the gut homeostasis can contribute to liver disease. In this review, the progress in the field within the last 3 years is summarized, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), autoimmune liver disease (AILD), and hepatocellular carcinoma (HCC). RECENT FINDINGS: Changes in the fecal virome and fungal mycobiome have been described in patients with various liver diseases. Several microbial derived metabolites including endogenous ethanol produced by bacteria, have been mechanistically linked to liver disease such as MASLD. Virulence factors encoded by gut bacteria contribute to ALD, AILD and HCC. Novel therapeutic approaches focused on the microbiome including phages, pre- and postbiotics have been successfully used in preclinical models. Fecal microbiota transplantation has been effective in attenuating liver disease. Probiotics are safe in patients with alcohol-associated hepatitis and improve liver disease and alcohol addiction. SUMMARY: The gut-liver axis plays a key role in the pathophysiology of liver diseases. Understanding the microbiota in liver disease can help to develop precise microbiota centered therapies.
Authors: David Schöler, Bernd Schnabl
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gut microbiota, gut-liver axis, liver disease, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune liver disease, hepatocellular carcinoma, fungal communities, virome, microbial metabolites, endogenous ethanol, bacterial virulence factors, phage therapy, prebiotics, postbiotics, fecal microbiota transplantation, probiotics, alcoholism, alcoholic hepatitis
Open Access status: green
Awards: Microbiome and intestinal innate immune response in alcoholic liver disease, G1523427655, Microbiome as therapeutic target in alcoholic hepatitis, San Diego Digestive Diseases Research Center, The Role of the Intestinal Mycobiome in Alcoholic Liver Disease, Southern California Research Center for ALPD and Cirrhosis, Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease
OpenAlex ID: W4391907080
